期刊文献+

EXPRESSION OF A MUTANT hTERT IN HUMAN BLADDER CARCINOMA CELL LINE T24 AND ITS CLINICAL SIGNIFICANCE

EXPRESSION OF A MUTANT hTERT IN HUMAN BLADDER CARCINOMA CELL LINE T24 AND ITS CLINICAL SIGNIFICANCE
下载PDF
导出
摘要 To construct a mutant pEGFP- hTERTexpression vector, to observe its steady expression intransfected human bladder carcinoma cell line T24 and its role in molecular regulatory mechanisms of telomerase, and to provide a new target gene for bladder cancer. Methods: PCR amplification was performed by using primers basedon the known gene sequence of hTERT. PCR productionwas cloned into plasmid pGEMT-T easy and the sequenceof mutant hTERT gene was analyzed. A recombinantmutant hTERT vector (pEGFP-hTERT) was constructed at the EcoR I and Sal I sites of the pEGFP-C1 vector. Aftertransfecting the fusion gene into bladder carcinoma cell line T24 by calcium phosphate-DNA coprecipitation, the steady expression of GFP-hTERT fusion protein was tested by fluorescent light microscopy. The proliferation changes ofbladder carcinoma cell line T24 were detected by lightmicroscopy and senescence correlated b-galactosidase staining. Results: Identification of pEGFP-hTERT byenzyme digestion showed that mutant hTERT fragment had been cloned into EcoR I and Sal I sites of the pEGFP-C1 vector. The steady expression of GFP-hTERT fusion protein was localized in the nucleus of transfected cells. Expression of senescence-associated b-galactosidase in transfected cells gradually increased with extended cultured time and cellgrowth was suppressed. Conclusion: The mutant-type hTERT gene suppresses the proliferation of bladder carcinoma cell line T24 by competitive effect on telomerase activity. This suggests that hTERT gene might be a suitable gene target for bladder cancer therapy. To construct a mutant pEGFP- hTERTexpression vector, to observe its steady expression intransfected human bladder carcinoma cell line T24 and its role in molecular regulatory mechanisms of telomerase, and to provide a new target gene for bladder cancer. Methods: PCR amplification was performed by using primers basedon the known gene sequence of hTERT. PCR productionwas cloned into plasmid pGEMT-T easy and the sequenceof mutant hTERT gene was analyzed. A recombinantmutant hTERT vector (pEGFP-hTERT) was constructed at the EcoR I and Sal I sites of the pEGFP-C1 vector. Aftertransfecting the fusion gene into bladder carcinoma cell line T24 by calcium phosphate-DNA coprecipitation, the steady expression of GFP-hTERT fusion protein was tested by fluorescent light microscopy. The proliferation changes ofbladder carcinoma cell line T24 were detected by lightmicroscopy and senescence correlated b-galactosidase staining. Results: Identification of pEGFP-hTERT byenzyme digestion showed that mutant hTERT fragment had been cloned into EcoR I and Sal I sites of the pEGFP-C1 vector. The steady expression of GFP-hTERT fusion protein was localized in the nucleus of transfected cells. Expression of senescence-associated b-galactosidase in transfected cells gradually increased with extended cultured time and cellgrowth was suppressed. Conclusion: The mutant-type hTERT gene suppresses the proliferation of bladder carcinoma cell line T24 by competitive effect on telomerase activity. This suggests that hTERT gene might be a suitable gene target for bladder cancer therapy.
出处 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2004年第2期79-84,共6页 中国癌症研究(英文版)
基金 This work was supported by the grants from the National Natural Science Foundation of China (No. 39870783) and the National 973 Project of China (No.G2000057001)
关键词 Bladder carcinoma Human telomerase reverse transcriptase gene (hTERT) Gene therapy Bladder carcinoma Human telomerase reverse transcriptase gene (hTERT) Gene therapy
  • 相关文献

参考文献15

  • 1[1]Meyerson M, Counter CM, Eaton EN, et al. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization[J]. Cell 1997; 90: 785-95.
  • 2[2]Urquidi V, Tarin D, Goodison S. Role of telomerase in cell senescence and oncogenesis[J]. Annu Rev Med 2000; 51: 65-79.
  • 3[3]Shay JW, Bacchetti S. A survey of telomerase activity in human cancer[J]. Eur J Cancer 1997; 33: 787-91.
  • 4[4]Rahat MA, Lahat N, Gazawi H, et al. Telomerase activity in paitent with transitional cell carcinoma: a preliminary study[J]. Cancer 1999; 85: 919-24.
  • 5[5]Arinaga M, Shimizu S, Gotoh K, et al. Expression of human telomerase subunit genes in primary lung cancer and its clinical significance[J]. Ann Thorac Surg 2000; 70: 401-5.
  • 6[6]Ito H, Kyo S, Kanaya T, et al. Expression of human telomerase subunits and correlation with telomerase activity in urothelial cancer[J]. Clin Cancer Res 1998; 4: 1603-8.
  • 7[7]Kelland LR. Telomerase inhibitors: Targeting the vulnerable end of cancer[J]? Anticancer Drugs 2000; 11: 503-13.
  • 8[8]Xia J, Peng Y, Mian IS, et al. Identification of functionally important domains in the N-terminal region of telomerase reverse transcriptase[J]. Mol Cell Biol 2000; 20: 5196-207.
  • 9[9]Stiffens S, Frank S, Fischer U, et al. Enhanced green fluorescent protein fusion proteins of herpes simplex virus type 1 thymidine kinase and cytochrome P450 4B1: Applications for prodrug-activating gene therapy[J]. Cancer Gene Ther 2000; 7: 806-12.
  • 10[10]Liu K, Schoonmaker MM, Levine BL, et al. Constitutive and regulated expression of telomerase reverse transcriptase (hTERT) in human lymphocytes[J]. Proc Natl Acad Sci USA 1999; 96: 5147-52.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部